Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
07
02
2020
accepted:
02
09
2020
revised:
14
08
2020
pubmed:
9
10
2020
medline:
6
7
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
We conducted a prospective clinical trial to investigate the safety and efficacy of plerixafor (P) in allogeneic peripheral blood stem cells (PBSC) donors with poor mobilization response to standard-dose granulocyte colony-stimulating factor (G-CSF), defined by <2 × 10
Identifiants
pubmed: 33028987
doi: 10.1038/s41409-020-01053-4
pii: 10.1038/s41409-020-01053-4
pmc: PMC8589660
doi:
Substances chimiques
Antigens, CD34
0
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
Granulocyte Colony-Stimulating Factor
143011-72-7
plerixafor
S915P5499N
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
635-645Commentaires et corrections
Type : ErratumIn
Références
Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transpl. 2016;51:778–85.
doi: 10.1038/bmt.2016.18
Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transpl. 2003;31:839–45.
doi: 10.1038/sj.bmt.1704019
Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009;114:2606–16.
doi: 10.1182/blood-2009-03-208355
Brown RA, Adkins D, Goodnough LT, Haug JS, Todd G, Wehde M, et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol. 1997;15:3067–74.
doi: 10.1200/JCO.1997.15.9.3067
Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134:517–25.
doi: 10.1111/j.1365-2141.2006.06223.x
Teipel R, Schetelig J, Kramer M, Schmidt H, Schmidt AH, Thiede C, et al. Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors. Transfusion. 2015;55:2855–63.
doi: 10.1111/trf.13239
DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–73.
doi: 10.1200/JCO.2008.20.7209
Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112:990–8.
doi: 10.1182/blood-2007-12-130179
Hauge AW, Haastrup EK, Sengelov H, Minulescu L, Dickmeiss E, Fischer-Nielsen A. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion. 2014;54:1055–8.
doi: 10.1111/trf.12383
Gattillo S, Marktel S, Rizzo L, Malato S, Malabarba L, Coppola M, et al. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. Transfusion. 2015;55:1993–2000.
doi: 10.1111/trf.13059
Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129:2680–92.
doi: 10.1182/blood-2016-09-739722
Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, et al. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019;3:875–83.
doi: 10.1182/bloodadvances.2018027599
Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy. 2003;5:55–65.
doi: 10.1080/14653240310000083
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.
doi: 10.1016/0197-2456(89)90015-9
Teipel R, Oelschlagel U, Wetzko K, Schmiedgen M, Kramer M, Rucker-Braun E, et al. Differences in cellular composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either granulocyte colony-stimulating factor (G-CSF) alone or G-CSF and plerixafor. Biol Blood Marrow Transpl. 2018;24:2171–7.
doi: 10.1016/j.bbmt.2018.06.023
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
doi: 10.1182/blood-2014-01-552984
Lemery SJ, Hsieh MM, Smith A, Rao S, Khuu HM, Theresa D, et al. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol. 2011;153:66–75.
doi: 10.1111/j.1365-2141.2010.08547.x
Pantin J, Purev E, Tian X, Cook L, Donohue-Jerussi T, Cho E, et al. Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102:600–9.
doi: 10.3324/haematol.2016.147132
Nadeau M, George L, Yeager AM, Anwer F, McBride A. Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation. Clin Case Rep. 2015;3:728–30.
doi: 10.1002/ccr3.327
Benboubker L, Watier H, Carion A, Georget MT, Desbois I, Colombat P, et al. Association between the SDF1-3’A allele and high levels of CD34(+) progenitor cells mobilized into peripheral blood in humans. Br J Haematol. 2001;113:247–50.
doi: 10.1046/j.1365-2141.2001.02717.x
Bogunia-Kubik K, Gieryng A, Dlubek D, Lange A. The CXCL12-3’A allele is associated with a higher mobilization yield of CD34 progenitors to the peripheral blood of healthy donors for allogeneic transplantation. Bone Marrow Transpl. 2009;44:273–8.
doi: 10.1038/bmt.2009.30
Lenk J, Bornhauser M, Kramer M, Holig K, Poppe-Thiede K, Schmidt H, et al. Sex and body mass index but not CXCL12 801 G/A polymorphism determine the efficacy of hematopoietic cell mobilization: a study in healthy volunteer donors. Biol Blood Marrow Transpl. 2013;19:1517–21.
doi: 10.1016/j.bbmt.2013.07.018
Szmigielska-Kaplon A, Szemraj J, Hamara K, Robak M, Wolska A, Pluta A, et al. Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies. Biol Blood Marrow Transpl. 2014;20:986–91.
doi: 10.1016/j.bbmt.2014.03.019
Shin S, Kim J, Kim-Wanner SZ, Bonig H, Cho SR, Kim S, et al. A novel association between relaxin receptor polymorphism and hematopoietic stem cell yield after mobilization. PLoS ONE. 2017;12:e0179986.
doi: 10.1371/journal.pone.0179986
Eyre TA, King AJ, Peniket A, Rocha V, Collins GP, Pawson R. Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest. Transfusion. 2014;54:1231–4.
doi: 10.1111/trf.12429
Bakanay SM, Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients. Bone Marrow Transpl. 2012;47:1154–63.
doi: 10.1038/bmt.2011.170
Karpova D, Brauninger S, Wiercinska E, Kramer A, Stock B, Graff J, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017;15:2.
doi: 10.1186/s12967-016-1107-2
de la Rubia J, Lorenzo JI, Torrabadella M, Marin P, Insunza A, Sanz MA. Basal CD34(+) cell count predicts peripheral blood progenitor cell mobilization and collection in healthy donors after administration of granulocyte colony-stimulating factor. Haematologica. 2004;89:1530–2.
pubmed: 15590408
pmcid: 15590408
Martino M, Gori M, Pitino A, Gentile M, Dattola A, Pontari A, et al. Basal CD34(+) cell count predicts peripheral blood stem cell mobilization in healthy donors after administration of granulocyte colony-stimulating factor: a longitudinal, prospective, observational, single-center, cohort study. Biol Blood Marrow Transpl. 2017;23:1215–20.
doi: 10.1016/j.bbmt.2017.03.024
Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, et al. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transpl. 2018;53:461–73.
doi: 10.1038/s41409-017-0051-y
Martino M, Gori M, Moscato T, Naso V, Ferreri A, Provenzano F, et al. The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts. Biol Blood Marrow Transpl. 2019;25:1568–91.
doi: 10.1016/j.bbmt.2019.04.011
Hölig K, Blechschmidt M, Von Bonin M. Successful enhancement of stem cell mobilization in G-CSF mobilized allogeneic donors by application of plerixafor (AMD 3100). In: Annual meeting of EBMT: Bone Marrow Transplantation, 2010. p S78.
Rutella S, Filippini P, Bertaina V, Li Pira G, Altomare L, Ceccarelli S, et al. Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-alphabeta/CD19-depleted haploidentical stem cell grafts. J Transl Med. 2014;12:240.
doi: 10.1186/s12967-014-0240-z
Arbez J, Saas P, Lamarthee B, Malard F, Couturier M, Mohty M, et al. Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease. Cytotherapy. 2015;17:948–55.
doi: 10.1016/j.jcyt.2015.02.009
Gaugler B, Arbez J, Legouill S, Tiberghien P, Moreau P, Derenne S, et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy. 2013;15:861–8.
doi: 10.1016/j.jcyt.2013.03.013
Tanhehco YC, Vogl DT, Stadtmauer EA, O’Doherty U. The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion. 2013;53:2314–26.
pubmed: 23362980
pmcid: 23362980
Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. Int J Hematol. 2017;105:141–52.
doi: 10.1007/s12185-016-2156-2
Hoggatt J, Singh P, Tate TA, Chou BK, Datari SR, Fukuda S, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem. Cell Cell. 2018;172:191–204 e110.
doi: 10.1016/j.cell.2017.11.003
Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, et al. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. J Clin Investig. 2019;129:2745–59.
doi: 10.1172/JCI124738